150 related articles for article (PubMed ID: 30955398)
1. Frequency of ALK and GD2 Expression in Neuroblastoma.
Aygün Z; Batur Ş; Emre Ş; Celkan T; Özman O; Comunoglu N
Fetal Pediatr Pathol; 2019 Aug; 38(4):326-334. PubMed ID: 30955398
[No Abstract] [Full Text] [Related]
2. Differential expression of delta-like gene and protein in neuroblastoma, ganglioneuroblastoma and ganglioneuroma.
Hsiao CC; Huang CC; Sheen JM; Tai MH; Chen CM; Huang LL; Chuang JH
Mod Pathol; 2005 May; 18(5):656-62. PubMed ID: 15605081
[TBL] [Abstract][Full Text] [Related]
3. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
4. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
Kim EK; Kim S
Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
[TBL] [Abstract][Full Text] [Related]
6. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
[TBL] [Abstract][Full Text] [Related]
7. Expression of GD2 ganglioside by untreated primary human neuroblastomas.
Wu ZL; Schwartz E; Seeger R; Ladisch S
Cancer Res; 1986 Jan; 46(1):440-3. PubMed ID: 3940209
[TBL] [Abstract][Full Text] [Related]
8. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
9. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
[TBL] [Abstract][Full Text] [Related]
10. The deubiquitinating enzyme UCHL1 is a favorable prognostic marker in neuroblastoma as it promotes neuronal differentiation.
Gu Y; Lv F; Xue M; Chen K; Cheng C; Ding X; Jin M; Xu G; Zhang Y; Wu Z; Zheng L; Wu Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):258. PubMed ID: 30359286
[TBL] [Abstract][Full Text] [Related]
11. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status.
Giannini G; Kim CJ; Di Marcotullio L; Manfioletti G; Cardinali B; Cerignoli F; Ristori E; Zani M; Frati L; Screpanti I; Guilino A
Br J Cancer; 2000 Dec; 83(11):1503-9. PubMed ID: 11076660
[TBL] [Abstract][Full Text] [Related]
12. [Pathology of peripheral neuroblastic tumors].
Wang L; He LJ; Shimada H
Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):283-8. PubMed ID: 22800533
[No Abstract] [Full Text] [Related]
13. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
[TBL] [Abstract][Full Text] [Related]
14. The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors.
de Torres C; Beleta H; Díaz R; Toran N; Rodríguez E; Lavarino C; García I; Acosta S; Suñol M; Mora J
Cancer; 2009 Jun; 115(12):2792-803. PubMed ID: 19350667
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.
Fagone P; Nicoletti F; Vecchio GM; Parenti R; Magro G
Acta Histochem; 2015 Oct; 117(8):820-3. PubMed ID: 26510683
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.
Tabyaoui I; Tahiri-Jouti N; Serhier Z; Bennani-Othmani M; Sibai H; Itri M; Benchekroun S; Zamiati S
Diagn Pathol; 2013 Feb; 8():39. PubMed ID: 23445749
[TBL] [Abstract][Full Text] [Related]
17. High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.
Tabyaoui I; Tahiri-Jouti N; Serhier Z; El Maani K; Cherkaoui S; Al Zemmouri M; Othmani MB; Zamiati S
Diagn Mol Pathol; 2013 Jun; 22(2):112-8. PubMed ID: 23628823
[TBL] [Abstract][Full Text] [Related]
18. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma.
Sariola H; Terävä H; Rapola J; Saarinen UM
Am J Clin Pathol; 1991 Aug; 96(2):248-52. PubMed ID: 1713742
[TBL] [Abstract][Full Text] [Related]
19. Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.
Shimada H; Ikegaki N
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053227
[TBL] [Abstract][Full Text] [Related]
20. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.
Bergaggio E; Tai WT; Aroldi A; Mecca C; Landoni E; Nüesch M; Mota I; Metovic J; Molinaro L; Ma L; Alvarado D; Ambrogio C; Voena C; Blasco RB; Li T; Klein D; Irvine DJ; Papotti M; Savoldo B; Dotti G; Chiarle R
Cancer Cell; 2023 Dec; 41(12):2100-2116.e10. PubMed ID: 38039964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]